Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam

Authors: María F. Mojica, Krisztina M. Papp‐Wallace, Magdalena A. Taracila, Melissa D. Barnes, Joseph Rutter, Michael R. Jacobs, John J. LiPuma, Thomas J. Walsh, Alejandro J. Vila, Robert A. Bonomo - Antimicrobial Agents and Chemotherapy 2017 cited by 75

ABSTRACT Stenotrophomonas maltophilia is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for S. maltophilia is urgent. We demonstrate the in vitro efficacy of aztreonam-avibactam (ATM-AVI) against S. maltophilia and kinetically characterize the inhibition of the L2 β-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of S. maltophilia , addressing an unmet medical need.